Alexion Pharmaceuticals, Inc. (ALXN)

126.01
NASDAQ
Prev Close 126.01
Day Low/High 0.00 / 0.00
52 Wk Low/High 92.56 / 141.86
Exchange NASDAQ
Shares Outstanding 224.30B
Market Cap 28.26B
Div & Yield N.A. (N.A)

Latest News

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Another Day of Rotation, but of a Different Sort

Another Day of Rotation, but of a Different Sort

Big-cap FAANG names and Apple, in particular, were the beneficiaries.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Alexion Suffers Quantitative Downgrade, Bearish Charts

Alexion Suffers Quantitative Downgrade, Bearish Charts

The path of least resistance is downward for Alexion.

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

Alexion New Outperform at RBC

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.

Now Up to the Plate, Today's Pinch Hitter, Bret Jensen!

It is good to be sitting in for Doug Kass here on the Daily Diary as we look to end the trading week on a positive note. It is also good to see the Yankees start to win close games again after losing so many of them in the weeks leading into the All...

Can Alexion Pharamaceuticals See an Upside Breakout?

Can Alexion Pharamaceuticals See an Upside Breakout?

A quantitative upgrade and chart patterns may do the trick.

Chipotle's Rally Could Resume

Chipotle's Rally Could Resume

I am starting to watch a couple of key price zones on the way down.

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today

We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.

Small-Cap Action Is Improving

Small-Cap Action Is Improving

But I don't have a lot of confidence in this market beyond the intraday action.

Looking for the End of a Trend

Looking for the End of a Trend

Alexion Pharmaceuticals presents a tradeable countertrend opportunity.

The Good, the Bad and the Ugly (Another Boring Edition)

"If you work for a living, why do you kill yourself working?" -- Tuco, The Ugly: " The Good, the Bad and the Ugly" https://www.youtube.com/watch? v=AFa1-kciCb4 No "Takeaways" today as the action was another painfully boring, uneventful and with litt...

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

Trader's Daily Notebook: As Long Weekend Nears, Volume Will Stay Low

If you want to stay active, you'll have to do more homework.

The Good, the Bad and the Ugly (Boring Edition)

"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, " The Good, the Bad and the Ugly" No "Takeaways" today as the action was kinda boring, uneventful and with little individual stock...

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Early-Morning Earnings Extravaganza

It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today. Biotech stalwarts Amgen and Celgene posted mixed results, while AbbVie seems to have beat both top- and ...

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion's Billion Dollar Deal Is Largely Wasted

Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.